Empower Clinics expands coronavirus testing in Arizona; sets new patient record volume for June

Empower Clinics Inc (CSE:CBDT) (OTCMKTS:EPWCF) has said demand for its services is at an 'all-time high' and it is expanding its coronavirus (COVID-19) testing days to five a week in Arizona as cases of the virus increase in the state. As previously reported, the life sciences and health group has established a four-phase antibody testing program using RAPID COVID-19 test kits to be rolled out nationally. READ: Empower Clinics searches for Dosed Wellness clinic site in Vancouver Official data has shown that over the last seven days, nearly 25,000 positive cases of coronavirus have been reported in Arizona, representing more than 25% of the total cases in the state since the pandemic began, and total reported cases now exceed 87,000 in the state, the group noted. "As a company and a health & wellness clinic operator, we are fortunate to be able to provide care and support to our thousands of patients each month," Steven McAuley, Empower's CEO said in a statement. "The demand for our services, are at an all-time high, requiring us to hire new staff and extend hours of operation. Our team continues to perform with complete professionalism, and safety, knowing the importance of the physician consultations we provide." Empower Clinics noted that it carried out 2,130 physician-patient consultations in June, setting a new historic milestone in patient volume for the month. The group also confirmed that the British Columbia Securities Commission has approved its application for a management cease trade order (MCTO), effective from June 16, which is necessary after it was unable to meet the reports filing deadline due to additional audit requirements by its auditor and increased operational limitations amid the pandemic. Empower said it continues to expect to report its annual filings, no later than July 15. As required under Canadian securities laws, it will provide a further update on or about July 14, the group added. Contact the author at giles@proactiveinvestors.com